Independent Research GmbH set a €76.00 ($90.48) price objective on STADA Arzneimittel AG (ETR:SAZ) in a research note released on Tuesday, August 29th. The firm currently has a sell rating on the stock.
Other research analysts also recently issued reports about the company. Commerzbank Ag set a €66.00 ($78.57) price target on STADA Arzneimittel AG and gave the company a neutral rating in a report on Monday, July 3rd. Warburg Research set a €66.00 ($78.57) target price on STADA Arzneimittel AG and gave the stock a sell rating in a research note on Thursday, June 8th. S&P Global set a €66.00 ($78.57) target price on STADA Arzneimittel AG and gave the stock a neutral rating in a research note on Saturday, May 20th. Finally, Kepler Capital Markets set a €58.00 ($69.05) target price on STADA Arzneimittel AG and gave the stock a sell rating in a research note on Wednesday, June 28th. Four equities research analysts have rated the stock with a sell rating and two have assigned a hold rating to the stock. STADA Arzneimittel AG presently has an average rating of Sell and a consensus target price of €69.07 ($82.23).
Shares of STADA Arzneimittel AG (SAZ) traded down 0.648% during trading on Tuesday, reaching €79.725. 599 shares of the company traded hands. The firm’s 50-day moving average is €72.86 and its 200-day moving average is €65.01. The stock has a market capitalization of €4.96 billion and a PE ratio of 52.693. STADA Arzneimittel AG has a 12-month low of €41.40 and a 12-month high of €84.20.
ILLEGAL ACTIVITY NOTICE: This piece was originally reported by BBNS and is owned by of BBNS. If you are viewing this piece on another website, it was illegally stolen and republished in violation of United States and international copyright and trademark law. The legal version of this piece can be accessed at https://baseballnewssource.com/markets/independent-research-gmbh-analysts-give-stada-arzneimittel-ag-saz-a-76-00-price-target/1565467.html.
STADA Arzneimittel AG Company Profile
STADA Arzneimittel Aktiengesellschaft engages in the development and marketing of active pharmaceutical ingredients for the health care and pharmaceutical markets worldwide. It operates through two segments, Generics and Branded Products. The Generics segment provides various generic active ingredients, including Tilidine naloxone for pain; Atorvastatin for elevated cholesterol levels; Pantoprazole for stomach ulcer/reflux; Diclofenac for pain/inflammation; and Enalapril for high blood pressure indications.
Receive News & Ratings for STADA Arzneimittel AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STADA Arzneimittel AG and related companies with our FREE daily email newsletter.